Glycated hemoglobin conversion average blood sugar level Normal blood sugar control target: fasting blood glucose 130 mg/dL, postprandial blood glucose 160-180 mg/dL, glycosylated hemoglobin below 7% (the control target will vary slightly according to different ages and clinical conditions). When the glycosylated hemoglobin is 8.5%: the average blood sugar is above 200 mg/dL, which is equivalent to fasting blood sugar close to 200 mg/dL, postprandial blood sugar 250-260 mg/dL, and such a value is far from the recommended target.
Dr. Li Hongyuan pointed out that those who do not old picture restoration meet the above-mentioned health insurance payment standards must use incretin at their own expense, which will cost an average of 3,000 to 4,000 yuan per month, not including outpatient registration, diagnosis and treatment, care and other related expenses, which accumulate over a long period of time. The amount is considerable. Therefore, under the current health insurance payment conditions, many people with diabetes are unable to use incretin therapy as soon as possible due to financial constraints, even if their blood sugar is not well controlled, further increasing the risk of cardio-renal comorbidities.
This result is not only a big blow to diabetes control, but also does not help to reduce the overall health care financial expenditure in the long run. Payback in 3 years! Diabetes Care Foundation: I hope to create a win-win situation by repairing the payment conditions of incretin health insurance Regarding this situation, Dr. Li Hongyuan emphasized that although he agrees that in order to maintain the long-term operation of Taiwan's medical system, health insurance financial considerations are necessary. However, in terms of long-term goals, the current health insurance payment standards for incretin are not only counterintuitive in clinical practice, but also inconsistent with the current international situation.